Clinical Trial Update: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating recombinant factor VIIa to prevent excessive bleeding in patients with congenital Hemophilia A or B with inhibitors undergoing major …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Coagulation Factor VIIa (Recombinant) (recombinant coagulation factor VIIa)

Snippet

Sponsor: Laboratoire français de Fractionnement et de Biotechnologies | Conditions: Hemophilia | Phase 3 | Status: TERMINATED